
Zepbound and Mounjaro, both from Lilly, take first and second place on the first Leading GLP-1 Meds list. Not only are they among the most used GLP-1s on the MeAgain platform, but members on Zepbound also recorded one of the highest median weight losses for the quarter in our real-world dataset. The continued demand for Lilly medicines came as Lilly lowered out-of-pocket costs, cutting Zepbound vial prices in December, launching the KwikPen at the same price in Q1 and listing Zepbound on TrumpRx from $299. Direct-to-consumer GLP-1s have continued to go mainstream. One in three new patients starting a branded weight-loss drug in 2025 began on Zepbound self-pay vials.
Compounded tirzepatide completes the top three. Its share of new members rose 20% from the end of 2025, making it the most common GLP-1 of choice for new members this quarter. The rise came as four state Medicaid programs stopped covering GLP-1s for weight loss in January, and it is not just Medicaid that is pulling back. The share of large employers covering the drugs for weight loss has fallen from 72% in 2025 to 60% this year.
+20%rise in compounded tirzepatide's share of new MeAgain members in Q1 2026














